Economic Evaluation of Brentuximab Vedotin for Persistent Hodgkin Lymphoma

Babashov, Vusal; Begen, Mehmet A.; Mangel, Joy; Zaric, Gregory S.

doi:10.3747/co.24.3369

Cited by 10 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The treatment of Hodgkin lymphoma (HL) has evolved over the last few decades based on PET‐CT assessment and risk‐stratified therapy (Cheson et al , ). Current costing studies in HL have focused more on the use of brentuximab in HL therapy (Engstrom, ; Babashov et al , ) and on the use of brentuximab in relapsed HL requiring salvage therapy and an autologous transplant (Hui et al , ; Parker et al , ). The available data on costing in upfront HL is scant, and comes from the pre‐PET era (Norum et al , ).…”

mentioning

confidence: 99%

Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting

et al. 2019

View full text Add to dashboard Cite

Summary Treatment of Hodgkin lymphoma (HL) has evolved with risk‐stratified therapy based on PET‐CT scan at multiple timepoints. In a resource constraint setting even a single PET‐CT scan ($400) is inaccessible to many patients, who are re‐assessed with only clinical examination, abdominal ultrasonogram and/or x‐ray (C/U/X) ($10). To compare clinical outcomes in patients with HL who have had suboptimal imaging after completion of chemotherapy for HL, with those who had a CT or PET‐CT, 283 patients were treated for HL from 2011 to 2015, and 268 patients completed six cycles of ABVD therapy with response assessment modality by CT/PET in 185 patients and by C/U/X in 83. There was no difference in the number of patients with advanced (64·1% vs. 61·1%; P = 0·650) or bulk disease (8·1% vs. 7·2%). A significantly higher number of patients in the CT/PET group received IFRT (25·4% vs. 7·7%; P = 0·0005). The three‐year overall survival and progression‐free survival of all treated patients (n = 283) was 83·5 ± 2·3% and 76·7 ± 2·6% respectively [median follow‐up 36 months (range 2–93)]. At three years, the overall relapse‐free survival (RFS) was 80·1 ± 2·5%, with RFS of 77 ± 3·2% vs. 85 ± 4·0% in the CT/PET group and C/U/X groups respectively (P = 0·349). There was no difference in RFS between the two groups either in early‐stage disease (88·1 ± 4·6% vs. 91·8 ± 5·6%; P = 0·671) or late‐stage disease (73·9 ± 4·8% vs. 81·3 ± 6·0%; P = 0·747). The only significant factor adversely affecting RFS was advanced disease (P = 0·004). Factors not affecting RFS were age (P = 0·763), sex (P = 0·925), bulk disease (P = 0·889) and imaging modality (P = 0·352). There was no difference in relapse rates between patients who had suboptimal imaging compared to those who had a PET/CT. It is possible to use these basic imaging modalities when resources are a constraint, with acceptable outcomes.

show abstract

mentioning

confidence: 99%

Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting

et al. 2019

View full text Add to dashboard Cite

show abstract

“…11,12 In addition, A-DLBCL can also be transformed from low-grade mucosa associated lymphoid tissue gastric tissue lymphoma. 13 It needs more research about whether A-DLBCL occurred in the skin, mucosa, and other sites have different characteristics.…”

Section: Discussionmentioning

confidence: 99%

Special clinicopathological features of anaplastic diffuse large B-cell lymphoma: a case report and literature review

Zhao

Wang

et al. 2022

Preprint

View full text Add to dashboard Cite

Anaplastic diffuse large B-cell lymphoma (A- DLBCL) is a mysterious and rare disease, its histopathological features have not been fully clarified toaday. This paper provides a case in the left axillary lymph node, there are a large number of pleomorphic centroblast-like cells with anaplastic characteristics and HRS-like cells in a nodular or follicular germinating center-like growth, which is consistent with diffuse large B-cell lymphoma, non-special type, anaplastic subtype. The results of immunohistochemistry showed that these tumor cells were positive for CD20, CD79ɑ, Pax5, LMO2, BCL6, IgD. Besides, CD21 showed FDC network and p53 was diffusely and strongly positive. Ki67 proliferation index was 80 ~ 90%. Tumor cells were no association with EB virus (EBV). Our case presents different morphological diversity from previously reported cases of A-DLBCL, which shows different clinicopathological features with common diffuse large B-cell lymphoma (DLBCL) and anaplastic large cell lymphoma (ALCL). Furthermore, we also review the most of article about ALCL and summarize the progress of its pathogenesis, treatment and prognosis in recent years.

show abstract

“…Три исследования оценива-ют применение БВ у пациентов с р / р ЛХ после аутоТГСК [31][32][33], одно -у пациентов с риском рецидива ЛХ после аутоТГСК [34].…”

Section: фармакоэкономические исследованияunclassified

“…В публикации Babashov et al был проведен анализ экономической эффективности терапии БВ для лечения р / р ЛХ после аутоТГСК с точки зрения канадского пла-тельщика [33]. Для этого была построена аналитическая модель принятия решений (на основе Марковских моде-лей) для расчета затрат на БВ по сравнению с поддержи-вающей терапией (монотерапия гемцитабином).…”

Section: фармакоэкономические исследованияunclassified

Targeted Drug Brentuximab Vedotin for Treatment of Relapsed or Refractory Cd30-Positive Hodgkin’s Lymphoma

et al. 2017

View full text Add to dashboard Cite

Economic Evaluation of Brentuximab Vedotin for Persistent Hodgkin Lymphoma

Abstract: BackgroundWe conducted a cost-effectiveness analysis of brentuximab vedotin for the treatment of relapsed and

Cited by 10 publications

References 32 publications

Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting

Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting

Special clinicopathological features of anaplastic diffuse large B-cell lymphoma: a case report and literature review

Targeted Drug Brentuximab Vedotin for Treatment of Relapsed or Refractory Cd30-Positive Hodgkin’s Lymphoma

Contact Info

Product

Resources

About